{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=8", "query": { "intervention": "Saline (Placebo Control)", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 3524, "total_pages": 353, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+%28Placebo+Control%29&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T14:57:22.886Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01840774", "title": "Modifying Virtual Reality Analgesia With Low-Dose Pain Medication", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Virtual Reality Therapy" ], "interventions": [ { "name": "Low-dose pain medication (Ketalar) and saline placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 60, "start_date": "2013-04", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2013-04-26", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01840774" }, { "nct_id": "NCT00845897", "title": "Botulinum Toxin Effects on Plantar Ulcer Recurrence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus", "Peripheral Neuropathy", "Plantar Ulcers" ], "interventions": [ { "name": "Botulinum Toxin", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 17, "start_date": "2005-03", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2012-02-03", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00845897" }, { "nct_id": "NCT01757418", "title": "Intravenous Gammaglobulin for Sickle Cell Pain Crises", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease", "Pain" ], "interventions": [ { "name": "Immune Globulin Intravenous (IVIG)", "type": "DRUG" }, { "name": "Normal saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "13 Years", "sex": "ALL", "summary": "6 Years to 13 Years" }, "enrollment_count": 300, "start_date": "2008-11", "completion_date": "2024-12-18", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01757418" }, { "nct_id": "NCT01295710", "title": "Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GVHD", "Adult Acute Myeloid Leukemia", "Adult Acute Lymphoid Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "US-ATG-F", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Neovii Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 260, "start_date": "2011-10-10", "completion_date": "2015-10-15", "has_results": true, "last_update_posted_date": "2019-04-09", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 26, "location_summary": "Duarte, California • Stanford, California • Gainesville, Florida + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01295710" }, { "nct_id": "NCT04518410", "title": "ACTIV-2: A Study for Outpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Coronavirus", "Covid19" ], "interventions": [ { "name": "bamlanivimab 7000mg", "type": "BIOLOGICAL" }, { "name": "BRII-196+BRII-198", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IV)", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IM)", "type": "BIOLOGICAL" }, { "name": "SNG001", "type": "DRUG" }, { "name": "Camostat", "type": "DRUG" }, { "name": "BMS-986414 + BMS-986413", "type": "BIOLOGICAL" }, { "name": "SAB-185 (3,840 Units/kg)", "type": "BIOLOGICAL" }, { "name": "SAB-185 (10,240 Units/kg)", "type": "BIOLOGICAL" }, { "name": "CASIRIVIMAB + IMDEVIMAB", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 7000mg", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 700mg", "type": "DRUG" }, { "name": "Placebo for BRII-196+BRII-198", "type": "DRUG" }, { "name": "Placebo for SNG001", "type": "DRUG" }, { "name": "Placebo for Camostat", "type": "DRUG" }, { "name": "Placebo for SAB-185 (low dose)", "type": "DRUG" }, { "name": "Placebo for BMS-986414 + BMS-986413", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IV)", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IM)", "type": "DRUG" }, { "name": "Placebo for SAB-185 (high dose)", "type": "DRUG" }, { "name": "bamlanivimab 700mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4044, "start_date": "2020-08-19", "completion_date": "2023-06-20", "has_results": true, "last_update_posted_date": "2024-08-02", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 207, "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518410" }, { "nct_id": "NCT04299490", "title": "Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sleep Disorder", "Healthy" ], "interventions": [ { "name": "Sleep Fragmentation", "type": "BEHAVIORAL" }, { "name": "Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)", "type": "DRUG" }, { "name": "Sleep Continuity Disruption", "type": "BEHAVIORAL" }, { "name": "Undisturbed Sleep", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "48 Years", "sex": "ALL", "summary": "18 Years to 48 Years" }, "enrollment_count": 148, "start_date": "2020-11-11", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04299490" }, { "nct_id": "NCT02469259", "title": "The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Stress Disorders, Post-Traumatic", "Alcoholism" ], "interventions": [ { "name": "Oxytocin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 88, "start_date": "2016-02", "completion_date": "2018-02-28", "has_results": false, "last_update_posted_date": "2019-05-21", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469259" }, { "nct_id": "NCT07868913", "title": "Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Suicidal Ideation" ], "interventions": [ { "name": "Ketamine Injectable Solution", "type": "DRUG" }, { "name": "Placebo Injection", "type": "OTHER" }, { "name": "Crisis Response Plan", "type": "BEHAVIORAL" }, { "name": "Safety Planning", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 200, "start_date": "2026-09-30", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 2, "location_summary": "Fort Hood, Texas • San Antonio, Texas", "locations": [ { "city": "Fort Hood", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07868913" }, { "nct_id": "NCT03113760", "title": "Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NLRC4-MAS", "XIAP Deficiency" ], "interventions": [ { "name": "Tadekinig alfa", "type": "DRUG" }, { "name": "0.9% sodium chloride", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AB2 Bio Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2017-07-21", "completion_date": "2023-11-02", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 6, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113760" }, { "nct_id": "NCT01866917", "title": "Study of TAP and Laparoscopic and Robotic Gynecologic Procedures and Obese Women", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Ropivacaine 0.5% 20cc injectate bilaterally", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2013-04", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-10-15T14:57:22.886Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01866917" } ] }